Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page
- Check5 days agoChange DetectedA site-wide NIH notice about using “Super Intelligence” instead of “Artificial Intelligence” appears, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe site footer’s revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision tag updated from v3.6.6 to v3.7.0, indicating a new site UI release rather than changes to the study content.SummaryDifference0.0%

- Check54 days agoChange DetectedThe history adds a new site revision v3.6.6 and removes the previous v3.6.5, indicating an updated release of the page framework.SummaryDifference0.0%

- Check61 days agoChange DetectedOutcome Measures (Results), Contacts/Locations, and Study Status have been added, signaling a newer version of the record with expanded access to current results, contact points, and status. The update reflects an enhanced organization of core study information for easier review and coordination.SummaryDifference0.3%

- Check75 days agoChange DetectedThe page’s revision label in the footer changed from v3.6.4 to v3.6.5, reflecting a new build of the site. This update appears to affect only metadata and not study content or user tasks.SummaryDifference0.0%

Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.